ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,460.48
-0.41%
US Tech 100
19,181.60
-0.43%
Dow Jones
39,118.86
-0.12%
Brent Oil
84.85
0.00%
Bitcoin
60,979.51
1.11%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) News

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateTimeSourceHeadlineSymbolCompany
06/26/20247:30AMGlobeNewswire Inc.Intellia Therapeutics Announces CFO TransitionNASDAQ:NTLAIntellia Therapeutics Inc
06/25/20243:30PMGlobeNewswire Inc.Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery PlatformNASDAQ:NTLAIntellia Therapeutics Inc
06/17/20247:30AMGlobeNewswire Inc.Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024NASDAQ:NTLAIntellia Therapeutics Inc
06/14/20244:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
06/14/20244:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
06/14/20244:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
06/14/20244:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
06/14/20247:30AMGlobeNewswire Inc.Intellia Therapeutics Names Brian Goff to its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
06/13/20244:59PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
06/02/20248:00AMGlobeNewswire Inc.Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
05/09/20244:25PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
05/09/20247:40AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
05/09/20247:30AMGlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
05/02/20247:30AMGlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
04/29/20247:30AMGlobeNewswire Inc.Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024NASDAQ:NTLAIntellia Therapeutics Inc
03/18/20247:30AMGlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyNASDAQ:NTLAIntellia Therapeutics Inc
03/05/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
03/05/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
03/05/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
03/05/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
03/05/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
02/26/20247:04AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NTLAIntellia Therapeutics Inc
02/23/20245:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
02/22/20244:11PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NTLAIntellia Therapeutics Inc
02/22/20244:02PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NTLAIntellia Therapeutics Inc
02/22/20247:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
02/22/20247:30AMGlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
02/15/20247:30AMBusiness WireIntellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
02/15/20247:30AMGlobeNewswire Inc.Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
02/14/20247:30AMGlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Your Recent History

USOTC
NNAX
New Momentum (PK)
USOTC
EMGE
Emergent Health (PK)
USOTC
CRTG
Coretec (QB)
USOTC
WDLF
Decentral Life (PK)
USOTC
GDVM
Global Developments (PK)
USOTC
GGSM
Gold and GemStone Mining (PK)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
AFFU
Affluence (PK)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
IQST
iQSTEL (QX)
NASDAQ
PLUG
Plug Power
USOTC
SMCE
SMC Entertainment (PK)
USOTC
RDGL
Vivos (QB)
USOTC
KEGS
1812 Brewing (PK)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
HHSE
Hannover House (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved